MedTrace Logo

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

NCT04956575 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 885

Last updated 2023-10-27

Study results available
· View outcomes & findings →

Summary

The study comprises 3 parts: Phase 1/2, Phase 2 Northern Hemisphere (NH), and Phase 2 extension. The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1010 vaccine.

Conditions

Interventions

BIOLOGICAL

mRNA-1010

Sterile liquid for injection

BIOLOGICAL

Placebo

0.9% sodium chloride solution for injection

BIOLOGICAL

Active Comparator

0.5 milliliter (mL) intramuscular (IM) injection

Sponsors & Collaborators

  • ModernaTX, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-06
Primary Completion
2022-09-27
Completion
2022-09-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04956575 on ClinicalTrials.gov